Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Emerging molecular drivers and biomarker targets in gastroesophageal cancers

Tatsuhiro Shibata • 9 Apr 2024
AACR 2024
Gastric Cancer Gastroesophageal Cancer Gastrointestinal Cancer Antibodies Checkpoint Inhibitors

Tatsuhiro Shibata, PhD, University of Tokyo, Tokyo, Japan, comments on emerging biomolecular therapeutic targets for the treatment of patients with gastric and gastroesophageal cancers. Promising biomarker targets include epidermal growth factor receptor 2 (EGFR2), claudins, and ones for immune checkpoint inhibitors (ICI). Prof. Shibata emphasizes that his session is being delivered at an opportune time, given the current state of scientific research on potential treatments for gastroesophageal cancer. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals